Shree Krishna Lifecare Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Shree Krishna Lifecare Pharmaceutical Export Portfolio Dataset — 4 Products, $238.1K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Shree Krishna Lifecare — Pharmaceutical Exporter Profile (2026) | 4 Products, $238.1K Trade | TransData Nexus

Shree Krishna Lifecare

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $238.1K Total Trade · DGFT Verified

Shree Krishna Lifecare is an Indian pharmaceutical exporter with a total trade value of $238.1K across 4 products in 1 therapeutic categories. Based on 40 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Pembrolizumab ($174.0K), Ibrutinib ($32.7K), Lapatinib ($18.5K).

Shree Krishna Lifecare — Export Portfolio & Destination Treemap

Shree Krishna Lifecare pharmaceutical export portfolio — 4 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Shree Krishna Lifecare? — Company Overview & Market Position

Shree Krishna Lifecare, established in 1996 as Shreekrishna Distributers, transitioned to its current name in 2017. The company is headquartered in Mumbai, India, at 606 Ratan Galaxie, Near Mehul Cine Ma, J N Road, Mulund West. It operates as a privately held entity, with ownership details not publicly disclosed. The Corporate Identification Number (CIN) is not available in the provided sources. Specific revenue figures and employee count are not publicly disclosed. The company's official website is sklifecare.com.

Shree Krishna Lifecare specializes in the export and distribution of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company has established a strong global presence, leveraging over two decades of market expertise to build sustainable relationships with clients. Their product portfolio spans various therapeutic categories, with a notable focus on oncology, antiretrovirals, and cardiometabolic diseases.

What Does Shree Krishna Lifecare Export? — Product Portfolio Analysis

Top Products by Export Value

1Pembrolizumab$174.0K 2

Product Portfolio — Top 4 by Export Value

Shree Krishna Lifecare exports 4 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Pembrolizumab	Advanced Oncology	$174.0K	10	9.0%	5
2	Ibrutinib	Advanced Oncology	$32.7K	16	3.3%	4
3	Lapatinib	Advanced Oncology	$18.5K	7	0.3%	6
4	Carfilzomib	Advanced Oncology	$12.9K	7	1.1%	7

Shree Krishna Lifecare exports 4 pharmaceutical products across 1 therapeutic categories with a total export value of $238.1K. The top category is Advanced Oncology (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Shree Krishna Lifecare — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Specific details regarding Shree Krishna Lifecare's manufacturing facilities, including locations, capacities, and specializations, are not publicly disclosed. The company emphasizes sourcing products from reputed manufacturers and authorized agents, ensuring the highest international quality standards.

3Key Leadership

The founder and visionary behind Shree Krishna Lifecare is Mr. Sandeep Modi, who established the company in 1996. His leadership is characterized by a strong work ethic and a commitment to transparency, fostering long-term relationships with clients. Specific details about other key executives, such as the CEO, CFO, and their respective roles, are not publicly available.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Shree Krishna Lifecare Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Shree Krishna Lifecare's export data indicates a focus on the advanced oncology therapeutic category, with products like Pembrolizumab and Ibrutinib. However, specific regulatory filings, approvals, and market access statuses in the US, EU, UK, Australia, and Japan are not publicly disclosed. The company's emphasis on sourcing from reputed manufacturers suggests adherence to international regulatory standards, but detailed information is not available.

2Emerging Markets

Shree Krishna Lifecare's export data does not specify shipments to Africa, Latin America, or Southeast Asia. The company's focus on oncology, antiretrovirals, and cardiometabolic diseases aligns with global health priorities, potentially facilitating access to emerging markets. However, specific information regarding WHO prequalification or market penetration in these regions is not publicly available.

3Geographic Strategy

Shree Krishna Lifecare's export data reveals a concentrated portfolio, with the top five products accounting for 100% of the export value. This indicates a high level of concentration risk. The company's strategic direction appears to focus on oncology, as evidenced by the prominence of products like Pembrolizumab and Ibrutinib. Diversification into other therapeutic areas or markets could mitigate potential risks associated with this concentration.

Shree Krishna Lifecare — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Shree Krishna Lifecare's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed. The company's emphasis on sourcing from reputed manufacturers suggests compliance with international regulatory standards, but detailed information is not available.

2WHO & EU GMP

Shree Krishna Lifecare's export data indicates a focus on oncology products, which are subject to stringent regulatory standards. However, specific information regarding WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, or European Directorate for the Quality of Medicines (EDQM) status is not publicly available. The company's commitment to quality suggests adherence to international standards, but detailed certifications are not disclosed.

3CDSCO & Indian Regulatory

Specific details regarding Shree Krishna Lifecare's manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), approvals from state drug controllers, or export No Objection Certificates (NOCs) are not publicly disclosed. The company's emphasis on sourcing from reputed manufacturers and authorized agents suggests compliance with Indian regulatory standards, but detailed information is not available.

Shree Krishna Lifecare — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Shree Krishna Lifecare operates in the competitive pharmaceutical export market, focusing on oncology products. While specific competitors are not identified in the provided data, the company's emphasis on sourcing from reputed manufacturers and authorized agents positions it to compete effectively in the global market. The concentration of its portfolio on a few products may limit its competitive edge compared to more diversified competitors.

2Key Differentiators

Shree Krishna Lifecare's key differentiators include its two-decade-long market expertise, commitment to sourcing genuine products from reputed manufacturers, and a strong global presence. The company's focus on oncology, antiretrovirals, and cardiometabolic diseases aligns with global health priorities, potentially enhancing its appeal in these therapeutic areas.

3Strategic Position

Shree Krishna Lifecare's current strategic direction appears to focus on exporting finished pharmaceutical formulations in the oncology therapeutic category. The company's emphasis on sourcing from reputed manufacturers and authorized agents suggests a commitment to quality and regulatory compliance. Future strategic directions may include diversification into other therapeutic areas or markets to mitigate concentration risks and enhance growth opportunities.

Buyer Due Diligence Brief — Evaluating Shree Krishna Lifecare as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Shree Krishna Lifecare's export data indicates a reliance on a limited number of products, with the top five accounting for 100% of the export value. This suggests a concentrated supplier base. The company's emphasis on sourcing from reputed manufacturers and authorized agents indicates a focus on quality and reliability. However, the lack of publicly available information regarding specific suppliers and their performance metrics limits a comprehensive assessment.

2Certifications to Verify

Importers should verify the following certifications when considering products from Shree Krishna Lifecare:

FDA Approval: Confirm that the products are approved by the U.S. Food and Drug Administration (FDA). Verification can be done through the FDA's official website or by contacting the manufacturer directly.

WHO-GMP Certification: Ensure that the manufacturing facilities comply with the World Health Organization's Good Manufacturing Practice (GMP) standards. This can be verified by checking the WHO's official list of prequalified manufacturers.

Frequently Asked Questions — Shree Krishna Lifecare

How many pharmaceutical products does Shree Krishna Lifecare export from India?

Shree Krishna Lifecare exports 4 pharmaceutical products across 1 therapeutic categories. The top exports are Pembrolizumab ($174.0K), Ibrutinib ($32.7K), Lapatinib ($18.5K), Carfilzomib ($12.9K). Total export value is $238.1K.

What is Shree Krishna Lifecare's total pharmaceutical export value?

Shree Krishna Lifecare's total pharmaceutical export value is $238.1K, based on 40 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Shree Krishna Lifecare cover?

Shree Krishna Lifecare exports across 1 therapeutic categories. The largest are Advanced Oncology (100.0%, 4 products).

Get Full Shree Krishna Lifecare Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.